Human disease
neurofibromatosis type 1
Mondo defines it as: “A clinically heterogeneous, neurocutaneous genetic disorder characterized by cafe-au-lait spots, iris Lisch nodules, axillary and inguinal freckling, and multiple neurofibromas.”
2 disease groups in OMIA reach this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 716 | Neurofibromatosis, generic | OMIA's OMIM numbers | 3 | Target evidence |
90.9
|
| 2241 | Neurofibromatosis, type 1 | Both routes | 1 | Target evidence |
89.9
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
| Human gene | Score | Evidence |
|---|---|---|
| NF1 | 0.88 | 15,452 |
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Mirdametinib | None of these genes | Approved |
| Selumetinib | None of these genes | Approved |
| Sirolimus | None of these genes | Phase 3 |
| Lamotrigine | None of these genes | Phase 2/3 |
| Acetylcysteine | None of these genes | Phase 2 |
| Aminolevulinic Acid | None of these genes | Phase 2 |
| Axitinib | None of these genes | Phase 2 |
| Bevacizumab | None of these genes | Phase 2 |
| Binimetinib | None of these genes | Phase 2 |
| Cabozantinib | None of these genes | Phase 2 |
| Cediranib | None of these genes | Phase 2 |
| Crizotinib | None of these genes | Phase 2 |
| Emvododstat | None of these genes | Phase 2 |
| Endostatin | None of these genes | Phase 2 |
| Everolimus | None of these genes | Phase 2 |
| Hiltonol | None of these genes | Phase 2 |
| Icotinib | None of these genes | Phase 2 |
| Imatinib | None of these genes | Phase 2 |
| Lapatinib | None of these genes | Phase 2 |
| Lovastatin | None of these genes | Phase 2 |
| Luvometinib | None of these genes | Phase 2 |
| Methotrexate | None of these genes | Phase 2 |
| Nedometinib | None of these genes | Phase 2 |
| Nerve Growth Factor | None of these genes | Phase 2 |
| Peginterferon Alfa-2b | None of these genes | Phase 2 |
| Pirfenidone | None of these genes | Phase 2 |
| Sunitinib | None of these genes | Phase 2 |
| Tipifarnib | None of these genes | Phase 2 |
| Tunlametinib | None of these genes | Phase 2 |
| Vinblastine | None of these genes | Phase 2 |
| Abemaciclib | None of these genes | Phase 1/2 |
| Alrizomadlin | None of these genes | Phase 1/2 |
| Pexidartinib | None of these genes | Phase 1/2 |
| Diphencyprone | None of these genes | Phase 1 |
| Sorafenib | None of these genes | Phase 1 |
| Talaporfin | None of these genes | Phase 1 |
| Talimogene Laherparepvec | None of these genes | Phase 1 |
| Nilotinib | None of these genes | Early phase 1 |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.